Business
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference
REDWOOD CITY, Calif. & BOSTON, March 31, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025.
About this update from Adicet Bio, Inc.
REDWOOD CITY, Calif. & BOSTON, March 31, 2025 --( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025. Details of the event are as follows: Panel: "CAR T Approaches in the Autoimmune Space" Date: Monday, April 7, 2025 Time: 3:00 p.m. ET About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20250331839401/en/ Contacts Adicet Bio, Inc. Investor and Media Contacts Investors: Anne Bowdidge [email protected] Janhavi Mohite Precision AQ 212-362-1200 [email protected] Media: Kerry Beth Daly [email protected]